Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer

@article{Ohyanagi2009PhaseIT,
  title={Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer},
  author={Fumiyoshi Ohyanagi and Nobuyuki Yamamoto and Atsushi Horiike and Hidehiko Harada and Takuyo Kozuka and Haruyasu Murakami and Kazunori Gomi and Toshiaki Takahashi and Madoka Morota and Tsunehiko Nishimura and Masahiro Endo and Yoji Nakamura and Asuka Tsuya and Takeshi Horai and Makoto Nishio},
  journal={British Journal of Cancer},
  year={2009},
  volume={101},
  pages={225 - 231}
}
Background:To assess the efficacy and safety of S-1 and cisplatin with concurrent thoracic radiation for unresectable stage III non-small-cell lung cancer (NSCLC).Methods:Eligible patients were 20–74 years old and had histologically or cytologically confirmed NSCLC, a performance status of 0–1, and no prior chemotherapy. Patients were treated with cisplatin (60 mg m−2 on day 1) and S-1 (orally at 40 mg m−2 per dose, b.i.d., on days 1–14), with the treatment repeated every 4 weeks for four… CONTINUE READING